We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Diagnostic Test for Malaria Compared

By LabMedica International staff writers
Posted on 13 Jun 2018
Print article
Image: The Deki Reader is a rugged, in vitro diagnostic device for use with commercially available lateral flow immunoassays, commonly known as rapid diagnostic tests (Photo courtesy of Fio Corporation).
Image: The Deki Reader is a rugged, in vitro diagnostic device for use with commercially available lateral flow immunoassays, commonly known as rapid diagnostic tests (Photo courtesy of Fio Corporation).
Malaria case management, consisting of early diagnosis and prompt effective treatment, remains a vital component of malaria control and elimination strategies. Although microscopy is a standard diagnostic tool for malaria and the gold standard, it is infrequently used because of unavailability of laboratory facilities and the absence of skilled readers in poor resource settings.

Rapid diagnostic tests (RDTs) are being advocated and used as alternative, or as an adjunct to microscopy at health facilities because they can be easily used by health workers with less training and equipment, and can be performed by non-specialists in remote settings. The RDTs provide fast test results for initiating or maintaining treatment of patients.

An international team of scientists working with the Kilimanjaro Christian Medical University College (Moshi, Tanzania) recruited a total of 1,293 among 1,423 outpatients with axillary temperature ≥ 37.5 °C, reported fever in the past 24 hours and/or other symptoms suggestive of malaria. The median age for study participants was 21 years and the majority of the participants (71.4%; 923/1293) were aged 18 to 24 years. More than two thirds (69.1%; 893/1293) of study participants were male.

In this study, the SD Bioline Malaria Antigen Pf/pan RDT that detects PfHRP2 (Plasmodium falciparum) and pLDH (pan) was used for malaria diagnosis alongside microscopy. Stained smears were examined by experienced senior microscopists. The Deki Reader (DR, Fio Corporation, Toronto, ON, Canada) provided automated sequential procedures to guide personnel on how to conduct the RDT test. After capturing an image and recognizing the brand of the RDT, the device prompts the user to remove the RDT from the device to proceed with taking blood samples from the patient.

The sensitivity of malaria rapid diagnostic test results interpreted by the Deki Reader was 94.1% and that of visual interpretation was 93.9%. The specificity of malaria rapid diagnostic test results was 71.8% and that of human interpretation was 72.0%. The positive predictive value of malaria RDT results by the Deki Reader and visual interpretation was 75.8 and 75.4%, respectively, while the negative predictive values were 92.8 and 92.4%, respectively. The accuracy of RDT as interpreted by DR and visually was 82.6 and 82.1%, respectively.

The authors concluded that there was no significant difference in performance of RDTs interpreted by either automated DR or visually by unskilled health workers. However, despite the similarities in performance parameters, the device has proven useful because it provides stepwise guidance on processing RDT, data transfer and reporting. The study was published on May 29, 2018, in the Malaria Journal.

Related Links:
Kilimanjaro Christian Medical University College
Fio Corporation

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.